Outcomes and molecular profiles in sarcomatoid carcinoma of unknown primary: the Mayo Clinic experience
The Oncologist · 2025
DOI: 10.1093/oncolo/oyae333 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Harry E Fuentes und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, United States. Hauptthemen laut MEDLINE: Neoplasms, Unknown Primary. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Sarcomatoid carcinomas (SC) are rare tumors with both epithelial and mesenchymal characteristics, linked to aggressive behavior and poor prognosis. Sarcomatoid carcinoma of unknown primary (SCUP) is an exceedingly rare subset with limited literature and no standardized management guidelines. This study aims to characterize the clinical presentations, treatment patterns, and genomic landscape of SCUP. Patients and Methods Data were retrospectively collected from the Mayo Clinic Rochester Cancer of Unknown Primary Registry. Patients included had biopsy-proven SC with no identifiable primary tumor despite comprehensive diagnostic evaluations. Baseline characteristics, immunohistochemistry (IHC) results, next-generation sequencing (NGS) data, and treatment outcomes were analyzed. Statistical analyses included descriptive statistics, Kaplan–Meier survival estimates, and Cox proportional hazards regression.
Results
Fifty-two SCUP patients were identified, with a median age of 60 years. Most patients presented with widely metastatic disease, particularly lytic bone lesions. Elevated alkaline phosphatase (ALP) was noted in nearly half of the patients. IHC showed high positivity for AE1/AE3 and OSCAR antibodies. Tumor NGS revealed 247 alterations, with TP53 being the most common mutation. Patients receiving definitive therapy had a median overall survival (OS) of 72 months, significantly longer than those receiving systemic therapy (14 months). Immunotherapy was a significant prognostic factor, reducing the risk of death by 90%.
Conclusions
This study provides essential insights into the clinical and genomic characteristics of SCUP, advocating for the integration of definitive therapy and immunotherapy in treatment protocols. Further prospective studies are needed to validate these findings and improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, United States.
- Department of Pathology, Mayo Clinic, Rochester, MN 55905, United States.
- Division of Hematology, Mayo Clinic, Rochester, MN 55905, United States.
ORCID-Profile: Harry E Fuentes
Zitieren
APA
Fuentes, H. E., Suleiman, R., Graham, R. P., Villasboas Bisneto, J. C., Garcia, J. J., & Halfdanarson, T. R. (2025). Outcomes and molecular profiles in sarcomatoid carcinoma of unknown primary: the Mayo Clinic experience. The Oncologist. https://doi.org/10.1093/oncolo/oyae333
Vancouver
Fuentes HE, Suleiman R, Graham RP, Villasboas Bisneto JC, Garcia JJ, Halfdanarson TR. Outcomes and molecular profiles in sarcomatoid carcinoma of unknown primary: the Mayo Clinic experience. The Oncologist. 2025. doi:10.1093/oncolo/oyae333
BibTeX
@article{Fuentes2025,
author = {Fuentes, Harry E and Suleiman, Riham and Graham, Rondell P and Villasboas Bisneto, Jose C and Garcia, Joaquin J and Halfdanarson, Thorvardur R},
title = {Outcomes and molecular profiles in sarcomatoid carcinoma of unknown primary: the Mayo Clinic experience},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyae333}
}
EUVIMED